KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Supernus Pharmaceuticals (SUPN) Accumulated Depreciation & Amortization (2016 - 2025)

Supernus Pharmaceuticals (SUPN) has disclosed Accumulated Depreciation & Amortization for 15 consecutive years, with $2.1 million as the latest value for Q4 2025.

  • Quarterly Accumulated Depreciation & Amortization fell 97.39% to $2.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.1 million through Dec 2025, down 97.39% year-over-year, with the annual reading at $2.1 million for FY2025, 97.39% down from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $2.1 million at Supernus Pharmaceuticals, up from $500000.0 in the prior quarter.
  • The five-year high for Accumulated Depreciation & Amortization was $80.4 million in Q4 2024, with the low at $500000.0 in Q3 2025.
  • Average Accumulated Depreciation & Amortization over 5 years is $13.3 million, with a median of $1.8 million recorded in 2021.
  • The sharpest move saw Accumulated Depreciation & Amortization plummeted 99.07% in 2023, then soared 3358.17% in 2024.
  • Over 5 years, Accumulated Depreciation & Amortization stood at $32.6 million in 2021, then crashed by 90.8% to $3.0 million in 2022, then dropped by 16.67% to $2.5 million in 2023, then soared by 3116.56% to $80.4 million in 2024, then plummeted by 97.39% to $2.1 million in 2025.
  • According to Business Quant data, Accumulated Depreciation & Amortization over the past three periods came in at $2.1 million, $500000.0, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.